截至发稿，崔蕾累计任职时间7年72天，现任基金资产总规模1227.6亿元，任职期间最佳基金回报 234.52%， 任职期间最差基金回报-15.93%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，南方基金旗下1只基金位居国新健康十大流通股东。南方中证1000ETF（512100）三季度减 持9.06万股，持有股数717.76万股，占流通股的比例为0.73%。根据测算，今日浮亏损失约401.95万元。 连续3天下跌期间浮亏损失574.21万元。 南方中证1000ETF（512100）成立日期2016年9月29日，最新规模766.3亿。今年以来收益8.51%，同类 排名1463/5531；近一年收益44.65%，同类排名1681/4215；成立以来收益24.1%。 南方中证1000ETF（512100）基金经理为崔蕾。 1月16日，国新健康跌5.18%，截至发稿，报10.25元/股，成交2.34亿元，换手率2.28%，总市值100.37亿 元 ...

南方中证1000ETF（512100）成立日期2016年9月29日，最新规模766.3亿。今年以来收益4.1%，同类排 名2067/5493；近一年收益40.84%，同类排名1761/4197；成立以来收益19.06%。 南方中证1000ETF（512100）基金经理为崔蕾。 1月8日，国新健康涨5.6%，截至发稿，报9.62元/股，成交1.23亿元，换手率1.34%，总市值94.20亿元。 资料显示，国新健康保障服务集团股份有限公司位于北京市东城区沙滩后街22号院2号楼、3号楼，成立 日期1987年8月28日，上市日期1992年11月30日，公司主营业务涉及医药电子商务、医疗福利管理等。 主营业务收入构成为：数字医保52.03%，数字医药26.17%，数字医疗17.70%，健康服务4.01%，房屋租 赁0.09%。 从国新健康十大流通股东角度 数据显示，南方基金旗下1只基金位居国新健康十大流通股东。南方中证1000ETF（512100）三季度减 持9.06万股，持有股数717.76万股，占流通股的比例为0.73%。根据测算，今日浮盈赚取约366.06万元。 截至发稿，崔蕾累计任职时间7年64天，现任基金资产 ...

Core Viewpoint - Guoxin Health's stock price has shown volatility, with a recent increase despite a year-to-date decline, indicating potential investor interest and market dynamics [1][2]. Group 1: Stock Performance - As of November 5, Guoxin Health's stock price rose by 2.27% to 10.35 CNY per share, with a trading volume of 1.52 billion CNY and a market capitalization of 10.135 billion CNY [1]. - Year-to-date, Guoxin Health's stock has decreased by 5.74%, but it has increased by 4.86% over the last five trading days [2]. Group 2: Financial Performance - For the period from January to September 2025, Guoxin Health reported a revenue of 170 million CNY, a year-on-year decrease of 14.87%, and a net profit attributable to shareholders of -138 million CNY, a significant decline of 347.32% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 47.7195 million CNY since its A-share listing [3]. Group 3: Shareholder Structure - As of September 30, 2025, Guoxin Health had 60,600 shareholders, a decrease of 8.38% from the previous period, with an average of 16,152 circulating shares per shareholder, an increase of 9.14% [2]. - The top ten circulating shareholders include Southern CSI 1000 ETF, which holds 7.1776 million shares, down by 90,600 shares from the previous period [3].

Core Points - The stock price of Guo Xin Health increased by 2.17% on October 31, reaching 9.88 CNY per share, with a total market value of 9.695 billion CNY [1] - Year-to-date, Guo Xin Health's stock price has decreased by 10.02%, with a recent 5-day increase of 0.41% and a 20-day decrease of 2.95% [2] - The company reported a revenue of 170 million CNY for the first nine months of 2025, a year-on-year decrease of 14.87%, and a net profit of -138 million CNY, a decrease of 347.32% [2] Financial Performance - Guo Xin Health's main business revenue composition includes: digital medical insurance (52.03%), digital pharmaceuticals (26.17%), digital healthcare (17.70%), health services (4.01%), and property leasing (0.09%) [2] - The company has cumulatively distributed 47.7195 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Guo Xin Health is 60,600, a decrease of 8.38% from the previous period [2] - The top ten circulating shareholders include Southern CSI 1000 ETF, holding 7.1776 million shares, a decrease of 90,600 shares from the previous period [3]

9月18日，国新健康涨5.37%，截至发稿，报10.80元/股，成交1.97亿元，换手率1.90%，总市值105.98亿 元。 资料显示，国新健康保障服务集团股份有限公司位于北京市东城区沙滩后街22号院2号楼、3号楼，成立 日期1987年8月28日，上市日期1992年11月30日，公司主营业务涉及医药电子商务、医疗福利管理等。 主营业务收入构成为：数字医保52.03%，数字医药26.17%，数字医疗17.70%，健康服务4.01%，房屋租 赁0.09%。 华夏中证1000ETF（159845）基金经理为赵宗庭。 截至发稿，赵宗庭累计任职时间8年157天，现任基金资产总规模3891.48亿元，任职期间最佳基金回报 116.15%， 任职期间最差基金回报-32.63%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从国新健康十大流通股东角度 数据显示，华夏基金旗下1只基金位居国新健康十大流通股东。华夏中证1000ETF（159845）二季度新 进十大流 ...

Group 1 - The core viewpoint of the news is that Guo Xin Health has experienced a stock price increase and a rise in shareholder numbers, despite reporting a net loss in its latest quarterly earnings [1][2] - As of March 31, 2025, Guo Xin Health has 70,199 shareholders, an increase of 8,037 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company operates primarily in four sectors: digital medical insurance, digital healthcare, digital pharmaceuticals, and health services, with its main products including bidding agency services for pharmaceuticals and medical devices [1] Group 2 - In the latest quarterly report for Q1 2025, Guo Xin Health reported revenue of 50.47 million yuan, a year-on-year increase of 5.33%, but a net loss of approximately 45.58 million yuan, representing a year-on-year decline of 12.86% [1] - The company's gross profit margin for the latest quarter was -14.79%, indicating challenges in profitability [1] - The current price-to-earnings (P/E) ratio for Guo Xin Health is significantly negative at -683.19, compared to the industry average of 116.83, highlighting its underperformance relative to peers [2]

Core Viewpoint - Guoxin Health's stock closed at 10.96 yuan, up 2.62%, with a latest price-to-book ratio of 7.74 and a total market capitalization of 10.755 billion yuan [1] Company Summary - Guoxin Health's main business areas are concentrated in digital medical insurance, digital healthcare, digital pharmaceuticals, and health services [1] - The company's primary products and services include drug and medical device bidding agency services, digital medical insurance, digital pharmaceuticals, and digital healthcare [1] - The "Four Libraries and Twenty-Four Systems" knowledge system of the company is recognized in the industry as the "Four Libraries Encyclopedia" [1] Financial Performance - For the third quarter of 2024, Guoxin Health reported operating revenue of 200 million yuan, a year-on-year increase of 24.40% [1] - The net profit for the same period was -30,946,674.76 yuan, representing a year-on-year decline of 71.49% [1] - The sales gross margin stood at 3.42% [1] Industry Comparison - Guoxin Health's price-to-earnings (P/E) ratio (TTM) is -4903.65, and the static P/E ratio is -134.79, with a price-to-book ratio of 7.74 [2] - The industry average P/E (TTM) is 119.51, and the industry median is 76.28 [2] - The total market capitalization of Guoxin Health is 10.755 billion yuan, compared to the industry average of 119.46 billion yuan [2]

Group 1 - The 27th meeting of the 11th Supervisory Board of Guo Xin Health was held on March 26, 2025, via telecommunication, with all three supervisors present [1] - The meeting approved the election of shareholder representative supervisors for the 12th Supervisory Board, as the term of the current board is about to expire [1][2] - The candidates for the 12th Supervisory Board, Cheng Zhipeng and Sun Fei, were nominated by the controlling shareholder and will be elected at the upcoming shareholders' meeting [2] Group 2 - The proposed remuneration standard for supervisors was discussed, with employee representative supervisors not receiving any supervisor allowance, only their job salary, while other supervisors will not receive allowances from the company [2] - The voting on the remuneration standard was conducted with all supervisors abstaining, and the proposal will be submitted directly to the shareholders' meeting for approval [2]

北京观韬律师事务所 法律意见书 观意字【2025】第BJ000091号 观韬律师事务所 GuantaoLawFirm 北京市西城区金融大街 5 号新盛大厦 B 座 19 层邮编：100032 电话：861066578066 传真：861066578016 E-mail：guantao@guantao.com http：//www.guantao.com 北京观韬律师事务所 法律意见书 释 义 关于 除非另有说明，本法律意见书中相关词语具有以下特定含义： 国新健康保障服务集团股份有限公司 限制性股票激励计划（第一期） 回购注销部分限制性股票的 | 国新健康/公司/上市公司 | 指 | 国新健康保障服务集团股份有限公司 | | --- | --- | --- | | 本次股权激励计划 | 指 | 国新健康保障服务集团股份有限公司限制性股票激励计 | | | | 划（第一期） | | 本次回购注销 | 指 | 国新健康保障服务集团股份有限公司关于限制性股票激 | | | | 励计划（第一期）回购注销部分限制性股票 | | 《激励计划（草案修订稿）》 | 指 | 《国新健康保障服务集团股份有限公司限制性股票激励 | ...

证券简称：国新健康 证券代码：000503 编号：2025-09 国新健康保障服务集团股份有限公司 国新健康保障服务集团股份有限公司 董 事 会 二零二五年二月二十日 1 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开第十一届董事会第三十六次会议，审议通过了《关于调整公司组织架 构的议案》。为进一步深化公司综合性改革，加快推进公司 AI in ALL 工作落地， 公司决定对组织架构进行调整：撤销 PBG 数据研发部，设立公司 AI 中心，统筹 负责公司 AI 底座建设等工作；法务部更名为法律风控部。公司相关制度中涉及 相关部门名称变更的，随之进行相应调整。 调整后的组织架构图如下： 特此公告。 关于调整公司组织架构的公告 ...